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Abstract
Background—Patients with smaller, single hepatocellular carcinoma (HCC) tumors and 
cirrhosis awaiting liver transplantation (LT) can have their tumors successfully eradicated with 
thermal ablation (TA). Accurate surveillance magnetic resonance imaging (MRI) reporting is 
critical for evaluating treatment response and tumor recurrence. The purpose of this study is to 
assess the validity of the Liver Imaging Reporting and Data System (LI-RADS) Treatment 
Response (LR-TR) criteria.
Methods—Retrospective analysis of a single-center database of patients with small HCC tumors 
(<3 cm in diameter) (who underwent both laparoscopic TA and LT from 2006 – 2017. Post-
ablation MRI were assigned LR-TR categories (Nonviable, Equivocal, and Viable) for ablated 
lesions and LI-RADS categories (probable or definite HCC) for untreated lesions. Interpretations 
were compared to the histopathology of the explanted liver after LT.
Results—Forty-five patients with 81 tumors (59 ablated and 22 untreated), mean size 2.2 cm, 
were included. Twenty-three (39%) of the ablated tumors had viable HCC on histopathology. The 
sensitivity/specificity of LR-TR categories (Nonviable/Equivocal vs Viable) of ablated tumors is 
30%/99%, with a PPV/NPV of 93%/69%. The sensitivity varies with residual tumor size. The 
sensitivity/specificity of LI-RADS 4 and 5 diagnostic criteria at detecting new HCC is 65%/94% 
with a PPV/NPV of 85%/84%. The inter-rater reliability (IRR) is high for LR-TR categories (90% 
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agreement, Cohen’s ĸ = 0.75) and LI-RADS LR-4 and LR-5 diagnostic categories (91% 
agreement, Cohen’s ĸ = 0.80).
Conclusions—In patients with HCC that are <3 cm in diameter, the LR-TR criteria after TA has 
high IRR but low sensitivity suggesting that the LR-TR categories are precise but inaccurate. The 
low sensitivity may be secondary to thermal ablation’s disruption in the local blood flow of the 
tissue which could affect the arterial enhancement phase on MRI. Additional investigation and 
new technologies may be necessary to improve imaging after ablation.
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Introduction:
Liver transplantation offers patients with cirrhosis and hepatocellular carcinoma (HCC) the 
best opportunity for long-term cancer-free survival.1 However, transplantation is only 
available for patients who meet the Milan Criteria.2–4 Locoregional therapies are used to 
prevent the tumor burden from progressing while the patient awaits transplantation.2,3,5 
Tumor ablation with either radiofrequency (RFA) or microwave ablation (MWA) is 
recommended as a locoregional bridging therapy by the American Association for the Study 
of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) 
and is particularly effective for single smaller tumors (e.g. <3 cm).3,5 Ablation reduces 
dropout rates from liver transplantation waitlists by safely preventing tumor progression 
without causing hepatic decompensation.6,7 Ablation also has higher rates of complete 
tumor necrosis compared to alternative strategies to control tumor growth (e.g., transcatheter 
arterial chemoembolization (TACE)).3,5,8–11
Following treatment with ablation, patients must undergo serial surveillance imaging with 
high-field magnetic resonance imaging (MRI) or contrast-enhanced computed tomography 
(CT) to evaluate for lesion necrosis, an indicator of successful ablation, while 
simultaneously looking for evidence of local or distant HCC recurrence. Accurately 
measuring the extent of necrosis is important to confirm clinical response or detect tumor 
recurrence, but classification systems have struggled with assessing post-ablation response.
12 Tumor response after locoregional therapy was initially based on assessment tools such as 
the Response Evaluation Criteria in Solid Tumors (RECIST), which was designed to 
evaluate tumor response to chemotherapy.13,14 These criteria suffered from poor inter-rater 
reliability (IRR) and were unsatisfactory for assessing response to ablation, given that post-
treatment tumor size does not adequately account for tumor necrosis.15–19 These limitations 
culminated in the development of the modified RECIST (mRECIST) and EASL criteria, 
which consider the reduction in viable tissue instead of tumor size. These tools also 
demonstrate better correlation with survival and have improved interrater variability.20–24 
These classification systems are used as reference standards for clinical trials but have not 
been widely adopted in clinical practice or in transplantation policies.25
In 2011, the American College of Radiology (ACR) launched the Liver Imaging Reporting 
and Data System (LI-RADS) in order to standardize interpretation and reporting of untreated 
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liver lesions in cirrhotic patients.26 This diagnostic reporting system categorizes an untreated 
hepatic lesion based on its benign or malignant HCC appearance ranging from 1 (definitely 
benign) to 5 (definitely HCC).27 In 2014, the ACR added a classification for treated nodules 
(LR-Treated) and in 2017, added the LI-RADS Tumor Response (LR-TR) classification 
system to assess the response after lesions are treated with locoregional therapy. Using this 
system, lesions are classified as nonviable, equivocal, or viable based on their post-treatment 
appearance on CT or MRI.27 While evaluating the response of HCC lesions to locoregional 
therapy has improved, the true sensitivity of MRI surveillance after ablation remains unclear. 
No studies have evaluated the accuracy of the LR-TR criteria on treated lesions in this 
patient population.
Accurate post-treatment surveillance of HCC is vital for patients awaiting liver 
transplantation since treatment response/tumor stage impacts long-term survival. Among 
patients who achieve complete pathologic response with locoregional therapy, HCC 
recurrence after transplantation is low (0–8.6% over 5 years).6,28–31 Conversely, failure to 
respond to therapy is associated with waitlist dropout due to tumor progression or post-
transplant recurrence, and decreased post-transplant survival.29,32–35 Given the importance 
of accurate post-treatment surveillance and uncertain test characteristics of post-ablation 
cross-sectional imaging, we evaluated the diagnostic accuracy and IRR of LR-TR categories 
using surveillance MRI obtained after thermal ablation of small HCC (<3 cm diameter) and 




This study is a single center retrospective review of all hepatocellular carcinoma (HCC) 
patients undergoing liver transplantation who had previously undergone laparoscopic liver 
ablations between January 2006 and December 2017. Ablations during this timeframe 
included both RFA and MWA and were performed by a single surgeon with the assistance of 
laparoscopic ultrasound. Patients were included in the study if they had HCC, at least one 
laparoscopic hepatic ablation prior to liver transplantation, and had at least one surveillance 
MRI post-ablation and prior to transplantation. Patients were excluded if their transplant was 
performed at another institution, if they had no surveillance MRI within the 3 months prior 
to transplant, if the MRI was poor quality (motion artifact, greater than 5mm imaging slices, 
or incomplete imaging of the liver), if there were deviations from MRI protocol, or if there 
was no complete pathology report of the explanted liver (Figure 1). No organs from executed 
prisoners were used in transplantation of this cohort. Approval was obtained from the 
University of North Carolina Institutional Review Board.
MRI Protocol
MRIs were performed using either a 1.5 T (Avanto®/Aera®, Siemens Medical System; GE-
Signa HDx®, GE Healthcare) or 3-T (Trio®/Skyra®, Siemens Medical System) MRI 
system with phased array torso coil used in all studies. LI-RADS is approved for use with 
both 1.5 and 3-T scanners as long as a phased array torso coil is used. We are not aware of 
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any data that 3-T scanners have improved sensitivity for identifying HCC recurrence and 
there is no specific preference for 3-T scanners within current AASLD guidelines.3 Our 
standard abdominal MRI protocol included the following sequences: axial unenhanced T1-
weighted dual-echo inphase/out-of-phase 2D gradient-echo sequence, coronal T2-weighted 
half-Fourier single-shot fast spin-echo sequence, axial T2-weighted half-Fourier single-shot 
fast spin-echo sequence with and without fat suppression, and axial fat-suppressed 3D 
gradient-echo sequences were used to perform dynamic contrast-enhanced study. The 
hepatobiliary phase images were acquired at 20 minutes after injection of Gadoxetate 
disodium and 90–150 minutes after injection of Gabobenate dimeglumine using fat-
suppressed 3D gradient-echo sequences. Subtraction imaging was used when available but 
was not routinely performed on all MRI imaging.
The intravenous gadolinium-based contrast agents were administered at a dose of 0.1 
mmol/kg using a power-injection system (Spectris Solaris® EP, Medrad, Pittsburgh, PA) at a 
rate of 2 mL/s followed by 20 mL saline flush.
Image Analysis
The last MRI before liver transplantation was reviewed independently by two board-certified 
radiologists with fellowship training in abdominal imaging. The radiologists were allowed to 
review prior MRIs if available but were blinded to pathologic outcome of the explanted liver. 
Each radiologist independently scored the lesions based on the LR-TR and LI-RADS 
diagnostic categories.25,26 At the time of review, both radiologists had more than 9 years 
experience in liver MRI interpretation and more than 5 years experience applying LI-RADS 
to MRI. The previously ablated tumors were assigned one of three LR-TR categories: LR-
TR Nonviable (for probably or definitely not viable), LR-TR Equivocal (for equivocally 
viable), or LR-TR Viable (for probably or definitely viable). The LI-RADS diagnostic 
categories were used for non-ablated lesions seen on MRI. Only lesions that met LI-RADS 
criteria for LR-4 (probably HCC) or LR-5 (definitely HCC) were recorded, since these 
lesions would warrant further locoregional treatment.
Reference Standards
The gold standard for residual or new HCC involves histopathologic examination of the 
native explanted liver after liver transplantation. Each native liver underwent full 
histopathologic examination including gross and microscopic assessment. Pathology reports 
of the explanted liver were reviewed and matched with reader assignment of LR-TR or LI-
RADS diagnostic categories based on Couinaud classification of hepatic segments. If no 
new lesions were identified on pathology, this was also noted. In cases where the lesion 
location was ambiguous or spanning more than one liver segment, pathology and imaging 
were concurrently reviewed to localize the lesion after LR-TR or LI-RADS diagnostics were 
assigned.
Variables and Outcomes
The main outcomes of this study are the determination of the sensitivity, specificity, and IRR 
of LR-TR in detecting residual viable tumor. The primary outcomes were evaluated by 
comparing the LR-TR categories to the histopathology of each tumor from the explanted 
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liver after transplantation. In the initial analysis, detectable disease on MRI was defined as 
LR-TR Viable alone. A separate analysis was carried out defining detectable disease on MRI 
as LR-TR Viable or LR-TR Equivocal. The IRR was obtained by comparing the LR-TR 
categories assigned by each radiologist for each individual lesion.
Secondary outcomes include the sensitivity, specificity, and IRR of LI-RADS diagnostic 
categories at detecting untreated HCC. New disease is defined as the presence of a LI-RADS 
4 or 5 lesion seen on MRI. For IRR, LI-RADS 4 and 5 categories assigned by each 
radiologist are treated as separate entities.
Ablation characteristics include lesion location (Couinaud classification), year of ablation, 
and use of imaging guidance for ablation (Pathfinder Navigation Guidance). Post-ablation 
tumor characteristics include viability of ablated tumor, size of residual tumor, 
differentiation of tumor, presence of lymphovascular invasion, and presence of perineural 
invasion. Additionally, the number of post-ablation surveillance MRIs obtained prior to 
transplant was collected.
Statistical Analysis
Overall and radiologist-specific sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV), and accuracy are calculated. LR-TR has three categories 
for classifying an ablated lesion they are: Nonviable, Equivocal, or Viable. LR-TR is initially 
evaluated as a dichotomous outcome, with Nonviable and Equivocal combined in the same 
category as not detecting residual disease versus Viable as detecting residual disease. Further 
analysis in this study classified LR-TR Equivocal and Viable as identification of residual 
disease for comparison to the initial analyses. LI-RADS diagnostic categories are evaluated 
as a dichotomous outcome (LR-4/5 vs no lesion identified), only tumors ≥1 cm are included 
in this analysis.
IRR for both the LR-TR categories (LR-TR nonviable, LR-TR equivocal, and LR-TR 
viable) and LI-RADS diagnostic categories (LI-RADS 4 and 5 only) are evaluated using the 
percent agreement and Cohen’s kappa coefficient. The kappa coefficient was assessed using 
the Altman benchmarked scale with a value of ≤0.20 corresponding to poor agreement, 
0.21–0.40 corresponding to fair agreement, 0.41–0.60 corresponding to moderate agreement, 
0.61–0.80 corresponding to good agreement, and ≥0.81 corresponding to very good 
agreement.
Patients’ demographics, underlying disease characteristics, and ablation characteristics are 
summarized using descriptive statistics. Bivariate analyses compared ablation 
characteristics, tumor characteristics, and post-ablation imaging follow-up based on correct 
classification (Correct Classification vs Incorrect Classification) of ablated or new tumor 
seen on liver explant. Post-ablation imaging follow-up was recorded as the number of MRIs 
performed after thermal ablation and prior to liver transplantation. Chi-square and Student’s 
t-tests are performed for categorical and continuous variables.
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Logistic regression was used to evaluate the association between correct classification of 
both LR-TR categories and LI-RADS diagnostic categories to the number of post-ablation 
follow up images.
Statistical significance was set at p<0.05 and all tests were 2-sided. All statistical analyses 
were conducted using STATA 14.1 (StataCorp, Inc., College Station, TX).
Results
Patient population
A total of 442 patients were analyzed in the database and 45 patients met the inclusion 
criteria. The average age at the time of transplantation was 60 years old (SD ±6) and the 
majority of patients were male and non-Hispanic white (Table 1). The most common cause 
of cirrhosis was Hepatitis C virus. Patients had an average Child-Pugh Score of 7 (SD ±2) 
and MELD of 11 (SD ±4). The average time from ablation to liver transplant was 219 days 
(SD ±153) (Table 1) and patients had a median of 2.8 years of follow-up after LT. 22/59 
patients had tumors larger than 2 cm, and the mean number of tumors per patient was 1.9 
(SD ± 1.3) (Table 1).
A total of 81 tumors were identified on explanted liver histopathology, including 59 
previously ablated tumors and 22 untreated tumors. Of the 59 ablated tumors, 23 (39%) had 
viable HCC on final pathology, with an average viable tumor size of 2.2 cm (SD ±1.4). 
Among the 23 tumors with viable HCC on final histopathology, the mean time from ablation 
to LT was 209 days (SD ±124), mean time until first post-treatment MRI was 35 days (SD 
±18) and 22 of the tumors (95.7%) received their first post-treatment surveillance within 60 
days. Of these 23 tumors, three had radiographic evidence of local recurrence. One had first 
surveillance imaging at 20 days post-ablation and went on to receive TACE. The second had 
first surveillance imaging at 109 days post-ablation and went on to receive LT four months 
after recurrence. The third had no evidence of residual disease on first surveillance imaging 
(27 days post-ablation), but had recurrence noted on a subsequent MRI (118 days post-
ablation) and went on to receive LT one month after recurrence.
The majority of the ablations were performed in segments 7 and 8 (Table 2). The average 
size of untreated HCC is 1.3 cm (SD ±0.5), with the majority of these lesions located in 
segments 7 and 8 of the explanted liver (Table 3). Only three patients (7%) in this study were 
outside of Milan criteria based on final histopathology of their explanted liver and four 
patients (9%) developed an HCC recurrence, occurring on average 320 days after 
transplantation (range 146–684 days). Two of the 4 patients who had post-transplant 
recurrence of HCC were outside of Milan criteria.
Accuracy of LI-RADS
A total of 12 patients had LR-viable or equivocal lesions on their last pre-transplant MRI 
and 33 had LR-nonviable lesions. For LR-viable/equivocal lesions, the mean time from 
ablation to pre-LT MRI was 156 days (SD ±142) and mean time between last MRI to LT 
was 58 days (SD ±29). For LR-nonviable lesions the mean times from ablation to pre-LT 
MRI and last MRI to LT were 171 days (SD ±158) and 50 days (SD ±27), respectively.
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The overall sensitivity and specificity of LR-TR categories (Nonviable/Equivocal vs Viable) 
of ablated tumors is 30% and 99% respectively, with PPV and NPV of 93% and 69% 
respectively (Table 4). The sensitivity of LR-TR varied substantially by size- it was 0% for 
residual tumor size <1 cm, 36% for residual tumor 1–2 cm, and 41% for residual tumor >2 
cm (Table 4). The PPV and NPV is 0% and 88% for residual tumor size <1 cm, 83% and 
89% for size 1–2 cm, and 90% and 85% for size >2 cm (Table 4).
After adjusting the cutoff point for detection of residual tumor to include LR-TR Equivocal 
with LR-TR Viable, the overall sensitivity and specificity is 44% and 86% respectively, with 
PPV and NPV of 67% and 71%, respectively (Table 6). The sensitivity is 20% for residual 
tumor <1 cm, 43% for residual tumor 1–2 cm, and 55% for residual tumor >2 cm. (Table 4). 
The PPV and NPV were 17% and 89% for residual tumor size <1 cm, 38% and 89% for size 
1–2 cm, and 55% and 86% for size >2 cm (Table 6).
The overall sensitivity and specificity of LI-RADS 4 and 5 diagnostic criteria at detecting 
new HCC is 65% and 94% respectively, with a PPV of 85% and NPV of 84% (Table 5). The 
sensitivity for new tumors 1–2 cm is 63%, and >2 cm is 100% (Table 5). The PPV and NPV 
are 83% and 84% for residual tumor size 1–2 cm and 33% and 100% for size >2 cm (Table 
5).
Interrater reliability (IRR)
The IRR for LR-TR categories (Nonviable, Equivocal, and Viable) was good, with 90% 
agreement and Cohen’s kappa coefficient of 0.75 (SE ± 0.09). For the LI-RADS diagnostic 
categories (LR-4 and LR-5) the IRR was also good, with a 91% agreement and Cohen’s 
kappa coefficient of 0.80 (SE ± 0.08). The combined IRR for both LI-RADS diagnostic and 
treatment response categories had a 90% agreement and Cohen’s kappa coefficient of 0.87 
(SE ± 0.04).
Number of surveillance MRIs and correct diagnosing
Having 3 or more surveillance MRIs performed between the time of ablation and time of 
transplantation is significantly associated with a higher odds of correct classification by LR-
TR, compared to having only 1 MRI (OR 12.8, 95% CI 2.1, 78.6, p<0.01) (Table 7). No 
association is seen between the number of surveillance MRIs and correct identification of 
new lesions using the LI-RADS diagnostic categories, p=0.15 (Table 7).
Discussion
This is the first study to evaluate the diagnostic accuracy and interrater reliability of the LR-
TR categories after thermal ablation for small HCC. Our study finds a high IRR but a lower 
sensitivity (30%) than anticipated while maintaining a high IRR. The IRR is consistent with 
previous studies evaluating the interrater agreement of the LI-RADS diagnostic categories.
36–38 After changing the cutoff point for detecting disease to include LR-TR Equivocal, 
sensitivity remains low (44%), with a decrease in specificity and PPV. As the size of the 
residual disease increases, the sensitivity of the LR-TR scale improves, though it remains 
below 50%. Additionally, we are unable to detect any residual viable tumor that is less than 
1cm.
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While this is the first study to evaluate the sensitivity of the LR-TR criteria, previous studies 
using different imaging criteria have also demonstrated low sensitivities.39–41 One study 
comparing resected or explanted liver histopathology of tumors that had previously 
undergone locoregional therapy (TACE or ablation) found a 38% sensitivity and 83% 
specificity for detecting residual HCC simply using nodular arterial enhancement and 28% 
sensitivity and 89% specificity for washout seen on cross-sectional imaging.39 Both arterial 
enhancement and washout are included in the LR-TR Viable category and help define 
residual disease. Though Ehman et al did not study the LR-TR categories, their sensitivity 
analysis is consistent with our results. A smaller study evaluating the resection specimen or 
explanted native liver of 22 hepatocellular carcinomas that had received locoregional therapy 
(TACE or ablation) found cross-sectional imaging was 40% sensitive and 100% specific at 
detecting residual viable tumor.40 Another study looking at only tumors that underwent 
radiofrequency ablation found surveillance cross-sectional imaging is 36% sensitive and 
100% specific at identifying residual viable tumor.41 The applicability of these studies is 
limited by the use of either a combination of locoregional modalities (TACE and ablation) or 
the combination of cross-sectional imaging (CT and MRI) in their analyses. In contrast, our 
study examines a single locoregional therapy modality (thermal ablation) and a single 
imaging modality (gadolinium-enhanced MRI).
The sensitivity of the LI-RADS diagnostic criteria for identifying new tumors at least 1 cm 
in size (62%) is lower than previously reported. However, in the prior studies liver explant 
histopathology was not required to validate the diagnostic imaging. For example, a study 
looking at 240 patients who underwent MRI surveillance for HCC found the LI-RADS 4 
and 5 criteria to be 86% sensitive and 84% specific at detecting HCC. However, only 12% of 
the cohort used surgical specimens for the diagnoses while the other 88% used core biopsy 
or radiologic follow-up as the referent standard for true HCC.37 Core needle biopsy has a 
high false negative rate due to the inability to distinguish well-differentiated HCC from 
cirrhotic liver and the inaccuracy of targeting specimens.42,43 Another study found the LI-
RADS sensitivity and specificity to be 76% and 85%, but the true diagnosis of HCC was 
solely made by follow-up imaging in more than one-third of these patients.44 A more recent 
study using histopathology of the explanted liver reports a much lower sensitivity for LI-
RADS 4 (43%) and LI-RADS 5 (57%) lesions.45 Future studies may need to incorporate 
histopathologic diagnosis as the gold standard, since imaging criteria may not be as sensitive 
or specific as previously thought.
In the current study, laparoscopic ablation was 61% effective at causing complete tumor 
necrosis. This is better than the previously reported 50% viability after locoregional therapy 
(thermal ablation and TACE) found on explanted native liver after transplant.39 Other reports 
evaluating tumor necrosis after ablation need to be interpreted cautiously as many of them 
rely on core needle biopsy or surveillance imaging to determine complete necrosis.46–49
With both the LR-TR and LI-RADS diagnostic categories, we find under-classification of 
true HCC tumor burden. Prior studies have also demonstrated significant under-staging of 
radiographic imaging of HCC compared to the actual histopathologic burden.40,50 The lower 
sensitivity with LR-TR compared to the LI-RADS diagnostic categories may be due to 
disruption in blood flow to the ablation cavity that is caused by ablation itself. This 
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disruption in blood flow may lead to decreased arterial enhancement and washout on cross-
sectional imaging, thus affecting the ability to detect residual disease. This has potential 
consequences in staging patients awaiting transplantation and could also impact survival 
after transplantation. Prior studies have found that having a complete or near complete 
pathologic response after locoregional therapy improves both overall survival and disease-
free survival after liver transplantation.28,30 The largest of these studies, with over 500 
patients, found that the disease-specific survival was 99% in patients who had a complete 
pathologic response after locoregional therapy compared to 86% for patients with partial or 
no response.28 Therefore, having accurate diagnostic tools to evaluate residual and new HCC 
is of the utmost importance. We did find improved diagnostic accuracy of LR-TR 
categorization in patients who had three or more MRIs from the time of ablation to the time 
of transplantation. The number of previous diagnostic images should be considered when 
discussing further treatment of HCC. Additionally, the interpretation of LR-TR categories 
should be undertaken in a multidisciplinary setting taking into account both clinical and 
radiographic data.
Our study had many strengths, including using complete explanted liver for histopathologic 
exam. Additionally, we are able to evaluate a single locoregional therapy (thermal ablation) 
with the LR-TR categories in comparison to other studies that often have mixed locoregional 
therapies. There are limitations to this study. With its retrospective design we are not able to 
fully re-review the histopathology of the native explanted liver after transplantation. While 
significant detail is obtained on initial evaluation of the gross liver at the time of initial 
examination, it is not possible to re-create this evaluation or obtain additional data after the 
tissue no longer exists. Accurate size of the residual/recurrent HCC after ablation is also 
limited as the pathology reports only documented the longest axis of tumor. Many cases may 
have a narrow short axis measurement contributing to the low sensitivity. Additionally, the 
LI-RADS diagnostic criteria detects HCC in patients with cirrhosis who are at risk for HCC. 
Our use of the LI-RADS diagnostic criteria in this sample may have led to a higher PPV 
since this cohort was limited to patients who were already treated for HCC and therefore at a 
higher baseline risk for HCC than patients with cirrhosis alone. In addition, it is important to 
interpret our reported sensitivities and specificities in the context of the population in which 
they were derived (i.e. patients with adequate post-ablation imaging who went on to 
transplant) and the unavailability of subtraction imaging on all reviewed MRIs. Lastly, a 
minority of patients in our cohort had tumors bigger than 2.5 cm and our findings may 
therefore not be generalizable to patients with larger lesions or to the general population of 
patients who receive LRT prior to transplantation.
In conclusion, we demonstrate that using the LR-TR categories after thermal ablation for 
HCC has high precision but low accuracy. This may be due to the disruption of blood flow in 
the tissue, which may affect the arterial enhancement and washout seen on MRI. The 
accuracy did improve with an increase in the number of MRIs available for comparison from 
the time of ablation to the time of transplant. Based on the findings in our study we feel that 
future studies should emphasize incorporating histopathology as a gold standard. The 
ultimate goal involves better identification of those patients who are at greater risk of disease 
progression and/or recurrence.
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Abbreviations:
AASLD American Association for the Study of Liver Diseases
ACR American College of Radiology
CT computed tomography
EASL European Association for the Study of the Liver
HCC hepatocellular carcinoma
LI-RADS Liver Imaging Reporting and Data System
LR-TR Liver Imaging Reporting and Data System Treatment Response
MELD Model for End-Stage Liver Disease
MRI magnetic resonance imaging
MWA microwave ablation
NPV negative predictive value
PPV positive predictive value
RECIST Response Evaluation Criteria in Solid Tumors
RFA radiofrequency ablation
TACE transcatheter arterial chemoembolization
WHO World Health Organization
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Table 1:
Baseline Characteristics of Patients with Hepatocellular Carcinoma (HCC) who Underwent Liver Transplant 
between 2004–2017
Overall, n 45
ŧAge, mean (SD) 60 (6)
Male, n (%) 38 (75)




Cause of liver disease, n (%)  
Hepatitis C 24 (53)
Hepatitis C + EtOH 13 (29)
EtOH 2 (4)
NASH/NAFLD 2 (4)
Autoimmune Hepatitis 1 (2)
MELD, mean (SD) 11 (4)
Child-Pugh Score, mean (SD) 7 (1.5)
Child-Pugh A, n (%) 20 (44)
Child-Pugh B, n (%) 23 (51)
Child-Pugh C, n (%) 2 (4)
Pre-ablation AFP, median (IQR) 21 (5–66)
Time from ablation to first MRI (days), mean (SD) 34 (132)
Time from ablation to LT (days), mean (SD) 219 (15)
Time from last pre-LT MRI to LT (days), mean (SD) 51 (26)
Number of Tumors, mean (SD) 1.9 (1.3)
Number of MRIs Prior to LT, mean (SD) 2.3 (1.5)
1 image, n (%) 13 (29)
2 images, n (%) 19 (42)
3 images, n (%) 8 (18)
≥ 4 images, n (%) 5 (11)
ŧ
Age at the time of transplantation; NHW - non-Hispanic white; NHB - non-Hispanic black; EtOH - alcohol; NASH/NAFLD - non-alcoholic 
steatohepatitis/non-alcoholic fatty liver disease; MELD - Model for End-Stage Liver Disease; AFP - alpha fetoprotein; LT - liver transplant; SD - 
standard deviation; MRI - magnetic resonance imaging
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Table 2:








Viable, n (%) 23 (39) 8 (18) 15 (100) <0.001
Non-viable, n (%) 36 (61) 36 (82) 0
ŧLocation
II/III 12 (20) 10 (23) 2 (13) 0.31
IVA/IVB 5 (9) 3 (7) 2 (13)
V/VI 16 (27) 14 (32) 2 (13)
VII/VIII 26 (44) 17 (39) 9 (60)
Year of Ablation, n (%)
2006–2010 12 (20.3) 7 (15.91) 5 (33.3) 0.35
2011–2013 29 (49.2) 23 (52.3) 6 (40.0)
2014–2017 18 (30.5) 14 (31.8) 4 (26.7)
Type of Ablation
RFA 4 (7) 3 (7) 1 (7) 0.98
MWA 55 (93) 41 (93) 14 (93)
Pathfinder
Yes 33 (56) 26 (59) 7 (47) 0.40
No 26 (44) 18 (41) 8 (53)
Number of MRIs Prior to LT, mean (SD) 2.3 (1.5) 2.1 (0.6) 1.5 (0.5) <0.01
1 image, n (%) 13 (29) 6 (14) 7 (47) 0.02
2 images, n (%) 19 (42) 16 (36) 6 (40)
3 images, n (%) 8 (18) 14 (32) 2 (13)
≥ 4 images, n (%) 5 (11) 8 (18) 0
Size, mean (SD) 2.2 (1.4) 2.4 (0.3) 2.1 (1.7) 0.58
<1 cm, n (%) 5 (22) 0 5 (33) 0.09
1 cm - 2 cm, n(%) 7 (30) 3 (38) 4 (27) ref.
> 2 cm, n (%) 11 (48) 5 (62) 6 (40) 0.91
Differentiation
Well, n (%) 3 (13) 0 3 (20) 0.38
Moderate, n (%) 18 (78) 7 (87) 11 (73)
Poor, n (%) 2 (9) 1 (13) 1 (7)
LVI, n (%) 3 (13) 1 (13) 2 (13) 0.96
PNI, n (%) 0 0 0 -
ŧ
Location is based on Couinaud classification of hepatic segments; RFA - radiofrequency ablation; MWA - microwave ablation; Pathfinder - 
Pathfinder Navigation Guidance; LT - Liver transplant; SD - standard deviation; LVI - lymphovascular invasion; PNI - perineural invasion
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Table 3:








New HCC, n (%) 22 (40) 13 (29) 9 (90) <0.001
No HCC, n (%) 33 (60) 32 (71) 1 (10)
ŧLocation, n (%)
I 1 (5) 0 1 (11) 0.32
II/III 4 (18) 1 (8) 3 (33)
IVA/IVB 2 (9) 1 (8) 1 (11)
V/VI 4 (18) 3 (23) 1 (11)
VII/VIII 11 (50) 8 (62) 3 (33)
Year of Ablation, n (%)
2006–2010 15 (27) 13 (29) 2 (20) 0.35
2011–2013 23 (42) 20 (44) 3 (30)
2014–2017 17 (31) 12 (27) 5 (50)
Number of MRIs Prior to LT, mean (SD) 2.2 (1.5) 2.4 (1.5) 1.6 (0.7) 0.14
1 image, n (%) 18 (33) 13 (29) 5 (50) 0.44
2 images, n (%) 22 (40) 18 (40) 4 (40)
3 images, n (%) 10 (18) 9 (20) 1 (10)
≥ 4 images, n (%) 5 (9) 5 (11) 0
Size, mean (SD) 1.3 (0.5) 1.4 (0.1) 1.1 (0.4) 0.22
<1 cm, n (%) 5 (23) 2 (15) 3 (33) 0.47
1 cm - 2 cm, n(%) 16 (73) 10 (77) 6 (67)
> 2 cm, n (%) 1 (5) 1 (8) 0
Differentiation
Well, n (%) 1 (5) 0 1 (11) 0.22
Moderate, n (%) 21 (95) 13 (100) 8 (89)
Poor, n (%) 0 0 0
LVI, n (%) 3 (14) 2 (15) 1 (11) 0.77
PNI, n (%) 0 0 0 -
Class. - Classification;
ŧ
Location is based on Couinaud classification of hepatic segments; SD - Standard Deviation; LVI - lymphovascular invasion; PNI - perineural 
invasion
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Table 4:
Detection of Residual HCC after Thermal Ablation using LI-RADS Treatment Response Categories (LR-TR)
Observer 1 Observer 2 Combined
All Ablated Lesions (23/59 viable)
Sensitivity 30% (7/23) 30% (7/23) 30%
Specificity 97% (35/36) 100% (36/36) 99%
PPV 88% (7/8) 100% (7/7) 93%
NPV 69% (35/51) 69% (36/52) 69%
Accuracy 71% (42/59) 73% (43/59) 72%
Lesion < 1 cm (5/41 viable)
Sensitivity 0% (0/5) 0% (0/5) 0%
Specificity 97% (35/36) 100% (36/36) 99%
PPV 0% (0/1) 0% (0/0) 0%
NPV 88% (35/40) 88% (36/41) 88%
Accuracy 85% (35/41) 88% (36/41) 87%
Lesion 1–2 cm (7/43 viable)
Sensitivity 29% (2/7) 43% (3/7) 36%
Specificity 97% (35/36) 100% (36/36) 99%
PPV 67% (2/3) 100% (3/3) 83%
NPV 88% (35/40) 90% (36/40) 89%
Accuracy 86% (37/43) 91% (39/43) 88%
Lesion > 2 cm (11/47 viable)
Sensitivity 46% (5/11) 36% (4/11) 41%
Specificity 97% (35/36) 100% (36/36) 99%
PPV 83% (5/6) 100% (4/4) 90%
NPV 85% (35/41) 84% (36/43) 85%
Accuracy 85% (40/47) 85% (40/47) 85%
*
LI-RADS equivocal was treated as no residual tumor identified on MRI; PPV - positive predictive value; NPV - negative predictive value
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Table 5:
Detection of Residual HCC after Thermal Ablation using LR-TR categories with Variation in Cutoff Points
LR-TR Equivocal + Viable LR-TR Viable Only
Obs. 1 Obs. 2 Combined Obs. 1 Obs. 2 Combined
All Ablated Lesions (23/59 viable)
Sensitivity 44% (10/23) 44% (10/23) 44% 30% (7/23) 30% (7/23) 30%
Specificity 86% (31/36) 86% (31/36) 86% 97% (35/36) 100% (36/36) 99%
PPV 67% (10/15) 67% (10/15) 67% 88% (7/8) 100% (7/7) 93%
NPV 71% (31/44) 71% (31/44) 71% 69% (35/51) 69% (36/52) 69%
Accuracy 70% (41/59) 70% (41/59) 70% 71% (42/59) 73% (43/59) 72%
Lesion < 1 cm (5/41 viable)
Sensitivity 20% (1/5) 20% (1/5) 20% 0% (0/5) 0% (0/5) 0.0%
Specificity 86% (31/36) 86% (31/36) 86% 97% (35/36) 100% (36/36) 99%
PPV 17% (1/6) 17% (1/6) 17% 0% (0/1) 0% (0/0) 0%
NPV 87% (31/35) 89% (31/35) 89% 88% (35/40) 88% (36/41) 88%
Accuracy 78% (32/41) 78% (32/41) 78% 85% (35/41) 88% (36/41) 87%
Lesion 1–2 cm (7/43 viable)
Sensitivity 43% (3/7) 43% (3/7) 43% 29% (2/7) 43% (3/7) 36%
Specificity 86% (31/36) 86% (31/36) 86% 97% (35/36) 100% (36/36) 99%
PPV 38% (3/8) 38% (3/8) 38% 67% (2/3) 100% (3/3) 83%
NPV 89% (31/35) 89% (31/35) 89% 88% (35/40) 90% (36/40) 89%
Accuracy 79% (34/43) 79% (34/43) 79% 86% (37/43) 91% (39/43) 88%
Lesion > 2 cm (11/47 viable)
Sensitivity 55% (6/11) 55% (6/11) 55% 46% (5/11) 36% (4/11) 41%
Specificity 86% (31/36) 86% (31/36) 86% 97% (35/36) 100% (36/36) 99%
PPV 55% (6/11) 55% (6/11) 55% 83% (5/6) 100% (4/4) 90%
NPV 86% (31/36) 86% (31/36) 86% 85% (35/41) 84% (36/43) 85%
Accuracy 79% (37/47) 79% (37/47) 79% 85% (40/47) 85% (40/47) 85%
*
LI-RADS Equivocal was treated as detecting residual tumor identified on MRI; Obs. – Observer; PPV - positive predictive value; NPV - negative 
predictive value;
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Table 6:
Detection of New HCC using LI-RADS diagnosis categories
Observer 1 Observer 2 Combined
Lesions ≥ 1cm (17/49 new)
Sensitivity 65% (11/17) 59% (10/17) 62%
Specificity 94% (31/33) 97% (32/33) 96%
PPV 85% (11/13) 91% (10/11) 88%
NPV 84% (31/37) 82% (32/39) 83%
Accuracy 84% (42/50) 84% (42/50) 84%
Lesion 1–2 cm (16/49 new)
Sensitivity 63% (10/16) 56% (9/16) 59%
Specificity 94% (31/33) 97% (32/33) 96%
PPV 83% (10/12) 90% (9/10) 86%
NPV 84% (31/37) 82% (32/39) 83%
Accuracy 84% (41/49) 84% (41/49) 84%
Lesion > 2 cm (1/31 new)
Sensitivity 100% (1/1) 100% (1/1) 100%
Specificity 94% (31/33) 97% (32/33) 96%
PPV 33% (1/3) 50% (1/2) 40%
NPV 100% (31/31) 100% (32/32) 100%
Accuracy 94% (32/34) 97% (33/34) 96%
*
LI-RADS 4/5 were treated as new tumor identified on MRI; PPV - positive predictive value; NPV - negative predictive value;
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Table 7.
Odds Ratios for correct LI-RADS categorization of ablated tumors
LR-TR categories LI-RADS diagnostic categories
Number of MRIs Prior to LT OR (95% CI) p-value OR (95% CI) p-value
1 image ref. ref. ref. ref.
2 images 3.11 (0.74 – 13.11) 0.12 1.73 (0.39 – 7.72) 0.47
≥3 images 12.83 (2.10 – 78.60) <0.01 5.38 (0.55 – 52.43) 0.15
LR-TR - LI-RADS Treatment Response Categories (LR-TR Viable vs LR-TR Equivocal/Non-Viable); OR - odds ratio; CI - confidence interval; LT 
- liver transplant
Liver Transpl. Author manuscript; available in PMC 2021 February 01.
